Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration‑resistant prostate cancer. Results of The Uroncor Group (Uro‑Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR)

• J. Valero ^[1] ; P. Peleteiro ^[7] ; I. Henríquez ^[8] ; A. Conde ^[9] ; T. Piquer ^[10] ; A. Lozano ^[2] ; C. C. Soler ^[11] ; J. Muñoz ^[3] ; A. Illescas ^[12] ; J. Jove ^[13] ; M. M. Flores ^[4] ; J. Baquedano ^[4] ; P. Diezhandino ^[5] ; R. P. de Celis ^[14] ; E. H. Pardo ^[14] ; P. Samper ^[15] ; I. Villoslada ^[16] ; M. Eguiguren ^[6] ; V. Millan ^[17]
  1. [1] Hospital Universitario HM Sanchinarro

     Hospital Universitario HM Sanchinarro

     Madrid, España

     
  2. [2] Hospital Virgen de la Arrixaca

     Hospital Virgen de la Arrixaca

     Murcia, España

     
  3. [3] Hospital Infanta Cristina

     Hospital Infanta Cristina

     Parla, España

     
  4. [4] Hospital Universitario Arnau de Vilanova

     Hospital Universitario Arnau de Vilanova

     Lérida, España

     
  5. [5] Hospital Universitario de Valladolid

     Hospital Universitario de Valladolid

     Valladolid, España

     
  6. [6] Hospital Universitario de Donostia

     Hospital Universitario de Donostia

     San Sebastián, España

     
  7. [7] Hospital Clinico Universitario de Santiago de Compostela, Santiago, Spain
  8. [8] Hospital Universitario Sant Joan de Reus, Tarragona, Spain
  9. [9] Hospital La Fe de Valencia, Valencia, Spain
  10. [10] Hospital de Castellon, Castellón, Spain
  11. [11] Hospital Torrecardenas Almeria, Almería, Spain
  12. [12] Hospital Virgen de la Macarena de Sevilla, Sevilla, Spain
  13. [13] Instituto Catalan de Oncologia Badalona, Barcelona, Spain
  14. [14] Hospital Txagorritxu de Vitoria, Vitoria-Gasteiz, Spain
  15. [15] Hospital Universitario Rey Juan Carlos de Mostoles, Madrid, Spain
  16. [16] Hospital Gomez Ulla de Madrid, Madrid, Spain
  17. [17] Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 8, 2020, págs. 1378-1389
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • ntroduction The treatment of metastatic castration-resistant prostate cancer (mCRPC) has changed significantly in recent years. Inhibitors of androgen receptors have shown especially significant benefits in overall (OS) and progression-free sur - vival (PFS), with a good toxicity profile. Treatment selection depends on the patient’s individual clinical, radiological, and biological characteristics.

    Objective To describe treatment outcomes (efficacy, toxicity) in a cohort of patients with mCRPC in Spain.

    Materials and methods Multicenter, retrospective study of patients with mCRPC included in a database of the Urological Tumour Working Group (URONCOR) of the Spanish Society of Radiation Oncology (SEOR). Metastatic CRPC was defined according to the prostate cancer working group 3 (PCWG3) criteria. The Kaplan–Meier technique was used to evaluate OS and the Common Terminology Criteria for Adverse Events (CTCAE, v.4.0) were used to assess toxicity. Univariate and multivariate Cox regression analyses were performed to identify the factors significantly associated with OS.

    Results A total of 314 patients from 17 hospitals in Spain diagnosed with mCRPC between June 2010 and September 2017 were included in this study. Mean age at diagnosis was 68 years (range 45–89). At a median follow-up of 35 months, OS at 1, 3, and 5 years were 92%, 38%, and 28%, respectively. Grades 1–2 and grade 3 toxicity rates were, respectively, 68% and 19%. No grade 4 toxicities were observed. On the multivariate analysis, the following factors were significantly associated with OS: age (hazard ratio [HR] 0.42, p = 0.010), PSA value at diagnosis of mCRPC (HR 0.55, p = 0.008), and Gleason score (HR 0.61, p = 0.009).

    Conclusions Age, Gleason score, and PSA at diagnosis of mCRPC are independently associated with overall survival in patients with mCRPC. The efficacy and toxicity outcomes in this patient cohort treated in radiation oncology departments in Spain are consistent with previous reports.